Understanding how DNA damage in heart cells affects heart function
Mapping the cell specific DNA damage-induced molecular and bioelectrical responses in the 3D cardiac unit
This study is looking at how damage to the DNA in heart muscle cells can lead to heart failure, focusing on a protein called p53 and its effects on heart health, to help us understand how different cells in the heart work together when things go wrong.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Carnegie-Mellon University NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-10993186 on NIH RePORTER |
What this research studies
This research investigates how DNA damage in heart muscle cells, known as cardiomyocytes, triggers a response that may lead to heart failure. The team will explore the role of a protein called p53, which is activated by DNA damage, and how this affects the mitochondria and the release of signaling molecules that influence heart health. By using advanced techniques to introduce DNA damage specifically in cardiomyocytes, the researchers aim to uncover the complex interactions between different cell types in the heart and their contributions to cardiac dysfunction.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with a history of cardiovascular disease or heart failure, particularly those who may have experienced DNA damage due to various factors.
Not a fit: Patients without any cardiovascular issues or those who do not have a history of heart disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments for heart failure by targeting the underlying cellular mechanisms of DNA damage.
How similar studies have performed: Other research has shown promising results in understanding the role of DNA damage in heart disease, suggesting that this approach could yield valuable insights.
Where this research is happening
Pittsburgh, United States
- Carnegie-Mellon University — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Cohen-Karni, Tzahi — Carnegie-Mellon University
- Study coordinator: Cohen-Karni, Tzahi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.